It might be better to show the approvals of specific regions (USA, EU, JP, CHINA) as subtabs under Approval Summaries

this should be in the Approvals& Reg Tab.

I like this, but we don't have a systemic way to get this data now. The data that we have right now is not sufficient to produce this structure. I think will be ready for this after SEC info extraction pipeline is built.

No need for targets tab, this information should appear in the main page.

Mode of action should be added here as well: Kras | inhibitor for example. No need to change the field name though, targets is ok

We divide the marketed assets in three categories: Launch (< 2y), Growth (2-10y) and Established (>10y)

We do not calculate many of these fields for the moment. Until the congress we can stick to only 6 metrics in the current UI.

https://staging.bioloupe.com/company/17103

After the congress we might add some of these metrics as well.

We should add this field after the congress as we dot calculate it for the moment.

We should add this field after the congress as we dot calculate it for the moment.

Instead of Markete assets the website should appear in here.

Not all companies have marketed assets thus probably this should not appear in the main page.

Once you choose the phase, is there a need for a phase column? Probably phase column should exist only under 'All' tab.

there should be a column called 'Clinical trials' and it should show the NCT ID of the clinical trial where the drug is being studied.

Instead of indication there should be disease.

It would be nice to include the technology as well as a column. Also there might be 3 targets as well for one drug.

No need for this. Only big pharma gives dividend and small pharma (where we are interested in mostly) doesnt give any dividend.

It should be Trailing P/E.

We dont have this data but it would be nice to collect it, the name of the metric should be market cap/book value<br /> to be consistent with other metrics.

We dont have this data and also even if we had it would be deeply skewed as for many companies this number is infinite.

Enterprise Value/Revenue and Enterprise Value/EBITDA

metrics should be in here as well.

We dont have PEG as a metric right now.

This number should appear above in 'Pipeline by phase'.

Same for Marketed assets, the number already appears in the Pipeline by Phase as approved drugs.

Market Cap is already included in the financials tab. Thus no need for it to be in the main page.

We dont need the top sponsor (organization).

I don't know whether we need the companies (organization) tab. Will think more about this.

We have a different categorization of type of company (which should be called organization actually). There are 8 company types in the organisations table:

Type Pharmaceutical/Biotechnology <br /> Academic Institution/Hospita Other Type Diagnostic Clinical Research Organization (CRO) Investor Government/Regulatory Institution

I think trials is just a duplicated tab of 'Development Tab'. For now I think there is no need for a Trial Tab.

The columns in both subtabs: 'Drugs in Developement' and 'Drugs Discontinued / No Activity Reported' should have the following columns: Drug,Organization, Target, Action, Modality, Phase, Clinical Trial ID. I am not sure about the order yet though.

Near 'Drugs in Developement' in the right there should be another subtab called ' Drugs Discontinued / No Activity Reported'

Owner should be substituted with 'Organization' in every section, not just in targets.

No need for this column.

The name of the tab can change to 'Development Landscape'.

I dont think we need this tab at all. We can only show UniProt ID in the main page as a clickable entity.

I think this should go under news tab. We can infer recent activities from news and other sources, however we dont have a well-defined way to infer this from other sources yet.

We don't have a function for the target. We have a description but its not good and better not be shown. Thus no need for function. All the info that we have about targets is here: https://datalake.bioloupe.com/admin/targets/683

I like that we show whether a drug is breakthrough therapy designation, orphan or fast track. However this is information is important only if the drug is not approved. If it is approved from fda then there is no need to show them. Thus they should be showed only in the period that the drug is waiting for approval. If the approval fails and the drug is discontinued, it might be better to show this info under a different tab, like 'Regulatory History'.

Showing indication for a drug that has been newly approved is possible, but as the label expands it becomes very difficult as there might be more than 10 indications. Thus probably shouldn't be in the main page as an info.

What we call now and indication is an overall description of the disease and the population for which the drug can be used. Thus indication as a definition is only valid for approved drugs. Thus in our context there can't be any failed or investigational Indication. We currently show the diseases where the drug is being studied under the Trials tab. And we have a separate tab for indications of approved drugs, please see 'Approvals and Regulatory' tab at https://staging.bioloupe.com/drug/10333

We dont want to show who has owned the drug during the history, just the current organization and also its partners (if there are any). This tab should not exist and also the current organization should show in the main page. It is a very crucial info to be shown under a tab.

For we show only the abbreviation of the target and its mode of action thus KRAS G12C | inhibitor in this case. We dont show Organism Evidence or Affinity right now, thus these three fields should be deleted. A drug might have more than 1 target. Also target of the drug and its technology (in this case small molecule) is the first thing the user is interested in a drug, thus it should be shown in the main page and not in a separate tab.

We do not have the info for most of the fields in Chemistry. We can get them but they are not important. We have atc code and chembl but they are for internal use only and not for display. Especially codes from other databases like drugbank should not be there as we are not allowed to use it for commercial reasons. Thus Chemistry tab should be removed.